Current therapy of KRAS-mutant lung cancer

KRAS mutations are the most frequent gain-of-function alterations in patients with lung adenocarcinoma (LADC) in the Western world. Although they have been identified decades ago, prior efforts to target KRAS signaling with single-agent therapeutic approaches such as farnesyl transferase inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghimessy, Aron, Radeczky, Peter, Laszlo, Viktoria, Hegedus, Balazs, Renyi-Vamos, Ferenc, Fillinger, Janos, Klepetko, Walter, Lang, Christian, Dome, Balazs, Megyesfalvi, Zsolt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680319/
https://www.ncbi.nlm.nih.gov/pubmed/32548736
http://dx.doi.org/10.1007/s10555-020-09903-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680319/
https://www.ncbi.nlm.nih.gov/pubmed/32548736
http://dx.doi.org/10.1007/s10555-020-09903-9

Ejemplares similares